Publication:
Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019

dc.contributor.authorKissling, Esther
dc.contributor.authorRose, Angela Mc
dc.contributor.authorEmborg, Hanne-Dorthe
dc.contributor.authorGherasim, Alin Manuel
dc.contributor.authorPebody, Richard
dc.contributor.authorPozo Sanchez, Francisco
dc.contributor.authorTrebbien, Ramona
dc.contributor.authorMazagatos, Clara
dc.contributor.authorWhitaker, Heather
dc.contributor.authorValenciano, Marta
dc.contributor.authorEuropean IVE group
dc.contributor.authorLarrauri, Amparo
dc.contributor.authorCasas Flecha, Inmaculada
dc.contributor.authorDelgado-Sanz, Concepcion
dc.contributor.authorOliva Dominguez, Jesus Angel
dc.date.accessioned2020-01-29T11:50:04Z
dc.date.available2020-01-29T11:50:04Z
dc.date.issued2019
dc.description.abstractInfluenza A(H1N1)pdm09 and A(H3N2) viruses both circulated in Europe in October 2018-January 2019. Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32-43% against influenza A; higher against A(H1N1)pdm09 and lower against A(H3N2). Among hospitalised older adults, VE estimates were 34-38% against influenza A and slightly lower against A(H1N1)pdm09. Influenza vaccination is of continued benefit during the ongoing 2018/19 influenza season.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipFunding: ECDC has contributed to fund some of the study sites and the coordination of the EU-PC study. WHO-EURO has contributed to fund the Romanian site in EU-PC and EU-H. Epiconcept has contributed to fund the EU-H study.es_ES
dc.format.number8es_ES
dc.format.volume24es_ES
dc.identifier.citationEuro Surveill. 2019 Feb;24(8):1900121.es_ES
dc.identifier.doi10.2807/1560-7917.ES.2019.24.1900121es_ES
dc.identifier.e-issn1560-7917es_ES
dc.identifier.issn1560-7917es_ES
dc.identifier.journalEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletines_ES
dc.identifier.pubmedID30808440es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/8980
dc.language.isoenges_ES
dc.publisherEuropean Centre for Disease Prevention and Control (ECDC)
dc.relation.publisherversionhttps://doi.org/10.2807/1560-7917.ES.2019.24.1900121es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectEuropees_ES
dc.subjectInfluenzaes_ES
dc.subjectMulticentre studyes_ES
dc.subjectTest-negative designes_ES
dc.subjectVaccinationes_ES
dc.subjectVaccine effectivenesses_ES
dc.subjectVaccines and immunisationes_ES
dc.titleInterim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019es_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicatione264f82c-6c07-4aa5-9f71-45e555f6592b
relation.isAuthorOfPublication5611ffc3-de88-4908-b20a-9a15a58c060a
relation.isAuthorOfPublicatione177bf8c-3734-480b-a2ae-4ae67491776c
relation.isAuthorOfPublicatione77e1f2d-b4e2-4ba5-a853-c2795850dcae
relation.isAuthorOfPublicatione2df6e55-f1d3-423b-a72f-fd9a69cf5915
relation.isAuthorOfPublicatione89a616b-8c7b-43b9-b3df-2a44c45e0765
relation.isAuthorOfPublicatione5273a7c-5f8e-464e-bea8-d933a72965b7
relation.isAuthorOfPublication.latestForDiscoverye264f82c-6c07-4aa5-9f71-45e555f6592b
relation.isPublisherOfPublication844b1441-479c-4219-87e5-efc493160a02
relation.isPublisherOfPublication.latestForDiscovery844b1441-479c-4219-87e5-efc493160a02

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Interim201819InfluenzaVaccine_2019.pdf
Size:
562.72 KB
Format:
Adobe Portable Document Format
Description: